Compare Bristol-Myers Squibb Co (BMY) vs HP Inc (HPQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs HP Inc — how do they compare? Bristol-Myers Squibb Co trades at $58.69 (market cap $116.30B), while HP Inc trades at $23.78 (market cap $22.52B). The key difference: Bristol-Myers Squibb Co is far larger — about 5.2× HP Inc's market cap, and HP Inc pays the higher dividend (4.87%). Which is the better fit depends on your goals.
| BMY | HPQ | |
|---|---|---|
Market Cap | $116.30B | $22.52B |
Sector | Health | Technology |
52-Week High | $62.37 | $29.35 |
52-Week Low | $42.60 | $18.20 |
Enterprise Value | $152.24B | $29.69B |
Dividend Yield | 4.42% | 4.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
HPQ trades at $24.77, up 2.27% today, with a bullish technical outlook and strong earnings momentum, beating estimates for three consecutive quarters. The stock offers a 4.8% dividend yield and trades at attractive valuation multiples, including a P/E of 9.17 and P/S of 0.41. Recent partnerships with OpenAI and Ferrari highlight strategic moves to enhance AI capabilities and innovation in the PC market.
The outlook is positive due to undervaluation, dividend income, and AI-driven growth potential, but risks include PC market volatility, competitive pressures, and reliance on hardware sales. Analyst consensus is mixed with a hold rating, but technical indicators suggest near-term strength with support at $24 and resistance at $25-26.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About HP Inc
HP Incorporated is a leading provider of computers, printers, and printer supplies. The company's mains segments are personal systems and printing. Its personal systems segment contains notebooks, desktops, and workstations. Its printing segment contains supplies, consumer hardware, and commercial hardware. In 2015, Hewlett-Packard was separated into HP Incorporated and Hewlett Packard Enterprise and the Palo Alto, California-based HP Incorporated sells on a global scale.
Read more on HPQ →
